More importantly, DAGLA was identified as a prognosis-associated target and was found to promote HCC progression by inducing the EMT process and suppressing p57 accumulation in vivo and in vivo (Fig. 7L). The gene discussed is DAGLA; the disease is hepatocellular carcinoma.